Author

G. Boivin

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 7 Immunology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 7 Research Focus:host-pathogen & immune response· 6 Organism:human· 6 Assay:bulk RNA-seq· 4 Research Focus:drug response / drug discovery· 2 Organism:virus· 2 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1

Frequent Co-Authors

A. Traversier· 4 shared B. Lina· 4 shared B. Padey· 4 shared J. Carbonneau· 4 shared M. Rosa-Calatrava· 4 shared M.-E. Hamelin· 4 shared O. Terrier· 4 shared T. Julien· 4 shared

Activity by Year

2018-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersMicrobiology

A. Traversier

Mutual co-authors in cluster

Author profile →

9 papers

Recent·Most cited

Viral interference between severe acute respiratory syndrome coronavirus 2 and influenza A viruses

S. Gilbert-girard, J. Piret, J. Carbonneau, M. Henaut, N. Goyette, G. Boivin

This study investigates viral interference between SARS-CoV-2 and influenza A viruses, finding that influenza A, especially H3N2, interferes with SARS-CoV-2 through IFN response, while SARS-CoV-2 only interferes with H1N1.

bioRxiv · Feb 2, 2024Microbiology

In Vitro Selection of Remdesivir-Resistant SARS-CoV-2 Demonstrates High Barrier to Resistance.

L. Checkmahomed, V. Du Pont, N. C. Riola, J. Perry, J. Li, D. P. Porter, G. Boivin

This study shows that remdesivir resistance in SARS-CoV-2 develops slowly, with a single mutation conferring limited resistance.

bioRxiv · Feb 7, 2022Microbiology

A novel effective live-attenuated human metapneumovirus vaccine candidate produced in the serum-free suspension DuckCelt-T17 cell platform

C. Chupin, A. Pizzorno, A. Traversier, P. Brun, D. Ogonczyk-makowska, B. Padey, C. Milesi, V. Duliere, E. Laurent, T. Julien, M. Galloux, B. Lina, J.-F. Eleouet, K. Moreau, M.-E. Hamelin, , M. Rosa-Calatrava

This study evaluates the use of DuckCelt-T17 avian cells for producing a live-attenuated HMPV vaccine candidate, showing its efficiency and scalability.

bioRxiv · Aug 30, 2021 · PreprintImmunology

Impact of temperature on the affinity of SARS-CoV-2 Spike for ACE2

J. Prevost, J. Richard, R. Gasser, S. Ding, C. Fage, S. P. Anand, D. Adam, N. Gupta Vergara, A. Tauzin, M. Benlarbi, S. Y. Gong, G. Goyette, A. Prive, S. Moreira, H. Charest, , A. Finzi

This study investigates how temperature affects SARS-CoV-2 Spike protein affinity for ACE2, finding increased binding at low temperatures, which is mitigated by the N501Y mutation.

bioRxiv · Jul 9, 2021 · PreprintMicrobiology

Human Respiratory Syncytial Virus-induced immune signature of infection revealed by transcriptome analysis of clinical pediatric nasopharyngeal swab samples

C. Nicolas de Lamballerie, A. Pizzorno, J. Dubois, B. Padey, T. Julien, A. Traversier, J. Carbonneau, E. Orcel, B. Lina, M.-E. Hamelin, M. Roche, J. Textoris, G. Boivin, C. Legras-Lachuer, O. Terrier, M. Rosa-Calatrava

This study identifies an HRSV-induced immune signature in pediatric nasal wash samples using transcriptome analysis.

bioRxiv · May 20, 2020Microbiology

Strain-dependent impact of G and SH deletions provide new insights for live-attenuated HMPV vaccine development

J. Dubois, A. Pizzorno, M.-H. Cavanagh, B. Padey, C. Nicolas de Lamballerie, O. Uyar, M.-C. Venable, J. Carbonneau, A. Traversier, T. Julien, C. Couture, B. Lina, M.-E. Hamelin, O. Terrier, M. Rosa-Calatrava, G. Boivin

This study evaluates strain-dependent effects of G and SH deletions in HMPV to inform live-attenuated vaccine development, finding that SH-deleted A1/C-85473 virus is attenuated and protective in mice.

bioRxiv · Sep 25, 2019Microbiology

Molecular pathway of influenza pan-neuraminidase inhibitors resistance in an immunocompromised patient

Y. Abed, M. Schibler, L. Checkmahomed, J. Carbonneau, M.-C. Venable, F. Giannotti, A. R. Goncalves, L. Kaiser, G. Boivin

This study tracks the emergence of oseltamivir resistance and subsequent zanamivir resistance mutations in an immunocompromised patient infected with A(H1N1)pdm09 influenza virus.

bioRxiv · Sep 16, 2019Microbiology

Efficient and specific Ly6G+ cell depletion: A change in the current practices toward more relevant functional analyses of neutrophils

J. Faget, G. Boivin, P.-B. Ancey, A. Gkasti, J. Mussard, C. Engblom, C. Pfirschke, J. Vazquez, N. Bendriss-Vermare, C. Caux, M.-C. Vozenin, M. J. Pittet, M. Gunzer, E. Meylan

The paper compares anti-Gr1 and anti-Ly6G antibodies for neutrophil depletion, showing anti-Ly6G's inefficacy in C57BL/6 mice but its potential for specific depletion when combined with a secondary antibody.

bioRxiv · Dec 18, 2018 · PreprintImmunology

Repurposing of drugs as novel influenza inhibitors from clinical gene expression infection signatures

M. A. Pizzorno, O. Terrier, C. Nicolas de Lamballerie, T. Julien, B. Padey, A. Traversier, M. Roche, M.-E. Hamelin, C. Rheaume, S. Croze, V. Escuret, J. Poissy, B. Lina, C. Legras-Lachuer, J. Textoris, , M. Rosa-Calatrava

This paper identifies 35 FDA-approved drugs with antiviral potential against influenza using transcriptomic signatures, validates 31 in vitro, and highlights diltiazem as a promising candidate for Phase II clinical trials.

bioRxiv · Aug 27, 2018Microbiology